

Seroprevalence of SARS-CoV-2 Antibodies among vaccinated and non-vaccinated adults in the West Bank: Results of a repeated cross-sectional study

Faisal Awartani, Arab American University of Palestine (AAUP), Ramallah, Palestine, faisal.awartani@gmail.com

Faisal Awartani department of health sciences, AAUP, Ramallah, Palestine
Nouar Qutob, department of health sciences, AAUP, Ramallah, Palestine
Mohammad Asia, department of health sciences, AAUP, Ramallah, Palestine
Waleed Theib , department of health sciences, AAUP, Ramallah, Palestine

ABSTRACT

Background

Seroprevalence studies are known to provide better estimates of the proportion of people previously infected, which did not undertake diagnostic testing. Repeated cross-sectional serostudies are encouraged in the same locations to monitor trends overtime. The aim of this study was to assess the seroprevalence among a random sample of vaccinated and non-vaccinated Palestinian adults living in the West Bank region of Palestine, irrespective of the source of antibodies, be it due to infection with COVID-19 or due to vaccination or both.

Methods

This repeated cross-sectional study used serologic testing on a random sample of vaccinated and non-vaccinated adults, 18 years and older residing in 11 governorates of the West Bank region of Palestine. Antibodies/Blood samples were taken using Elecsys Anti-SARS-CoV-2 assay by using the Cobas Analyzer cobas e 411 (Roche) for detection of antibody seropositivity against COVID-19. Seroprevalence was estimated as the proportion of individuals who had a positive result in the total SARS-CoV-2 antibodies in the immunoassay. Sociodemographic information and medical history data was collected using a questionnaire.

Results

Among 1451 total participants enrolled in the study, serum samples were tested from 910 persons. Study findings from this randomly selected sample indicated a seroprevalence 75.9%, 95% CI (73.1-78.7). The seroprevalence results indicated that the prevalence of antibodies among those who reported that they were not infected and did not get vaccinated was 45.2% with 95% CI (39.9-50.5%).

The average age of participants was 37.6 years old. 49.2% were female and 50.8% were male. In relation to COVID-19, the following was found:

Conclusion

Our findings revealed a drastic rise in seroprevalence of SARS-CoV-2 antibodies. This information is useful for assessing the degree of herd immunity, and provides for better understanding of the pandemic. Population-based seroprevalence studies should be conducted periodically to monitor the SARS-CoV-2 seroprevalence in Palestine and inform policymakers about the efficacy of the surveillance system.

INTRODUCTION

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel virus that causes Coronavirus Disease 2019 (COVID-19) has infected over 460 million and caused the deaths of over six million people worldwide as of March 12, 2022 [1]. However, these figures underestimate the accurate cumulative prevalence or incidence of infection [2], due to accessibility of diagnostic testing, limited testing capacity [3] , and asymptomatic infections [4].

Globally, seroprevalence studies using serologic testing have been recognized to provide better estimates of COVID-19 infection rates and prevalence on a population level in different populations, by capturing individuals with mild or no symptoms and others who never underwent diagnostic testing [5]. Assessing the cumulative prevalence is critical to understanding disease transmission rates and for understanding the evolution of the pandemic [5, 6]. The true prevalence of infection is believed to be 12.5 times more than the number of PCR-reported infections [7] as there are many asymptomatic infections, which constitute the majority of all SARS-COV-2 infections, yet are less likely to present for diagnostic testing [8, 9]. Consequently, the accuracy of such seroprevalence studies has been doubted due to insufficient specificity of the serologic assay for a low prevalence population and due to potential sampling bias [10].

In March 2020 a nationwide lockdown was implemented in Palestine, to contain the spread of COVID-19. As of March 2022, approximately 580,165 infections have been recorded, and 5,326 people have died in Palestine [11]. Previously, the authors of this study undertook a cross-sectional study [12] which revealed 0% seroprevalence of SARS-CoV-2 among a random sample of adults in the general population in the West Bank region of Palestine. Other studies [13] conducted among Palestinian adults in the West Bank yielded a seroprevalence of 36% and 40%, respectively (World Health Organization and Palestine Ministry of Health, 2022). There is a lack of data on the percentage of undiagnosed Palestinian population with previous mild or asymptomatic COVID-19. This repeated cross-sectional study was conducted to assess the seroprevalence of SARS-CoV-2 among a national sample of vaccinated and non-vaccinated adults in the West Bank region of Palestine, irrespective of the source of antibodies, be it due to infection with COVID-19 or due to vaccination or both. It is hoped the substantial seroprevalence of anti-SARS-CoV-2 antibodies in the Palestinian population should provide some measure of protection against future waves of COVID-19 in the country.

METHODS

Study design and participants

This second cross-sectional study was conducted between September 14, 2021 and October 21, 2021 on a random sample of adults aged 18 years and above residing in 11 governorates in the West Bank, Palestine. The sample included 1451 individuals randomly selected from households using three-stage cluster sampling. The cluster of households or census tracts is considered to be a geographic location which is comprised of 124 households. The process for conducting cluster sampling included: (1) Selection of 125 census tracts (clusters) of households using the sampling frame provided by the Palestinian Central Bureau of Statistics (PCBS), (2) Selection of 16 households randomly from each cluster and (3) selection of individuals at random from the list of individuals who are over the age of 18 and belong to the selected household. The clusters were selected using probability proportional to size (PPS) sampling (Table 1). To select the number of

clusters within each population location: (1) the sampling interval (eg $SI=N/m$) which equals the total number of households divided by the total number of clusters need to be selected by the sample was calculated, (2) a random number R_0 between 0 and SI was calculated, and (3) calculated R_i as R_0+i*SI , a cluster is selected in L_i if R_i belongs to the interval $[C_{i-1}, C_i]$.

Location	# of households in the location	Cumulative
L1	X1	$C_1=X_1$
L2	X2	$C_2=X_1+X_2$
L3	X3	$C_3=X_1+X_2+X_3$
.	.	.
.	.	.
.	.	.
Lk-1	Xk-1	$C_{k-1}=X_1+X_2+\dots+X_{k-1}$
Lk	Xk	$C_k = X_1+X_2+\dots+X_k$

PPS, probability proportional to size.

Data Collection

Sociodemographic information, risk factors, medical history, and COVID-19 related information (eg. Symptoms (due to infection or due to vaccination); vaccination status) were obtained during a face-to-face interview from 1451 participants. Sample characteristics are presented in Table 2. Upon the interview, participants were asked if they would like to get tested for antibodies against COVID-19. Blood samples were collected from 911 participants. Blood samples were centrifuged, and serum was separated, labelled and stored at -20°C at AAUP laboratory until it was used.

Data collection was conducted by healthcare professionals at AAUP following standardized health protocols (World Health, 2020). Approval from the National Ethical Committee was obtained (PHRC/HC/737/20). Written informed consent was obtained from all participants before the interview and the blood sampling and approval of utilization of tests was obtained from Medicare laboratories Participation was completely voluntary and all participants were informed that all the information collected would be anonymous and treated as confidential.

Sars-CoV-2 Antibody Testing

Presence of SARS-CoV-2 antibodies was investigated with the Elecsys Anti-SARS-CoV-2 assay by using the Cobas Analyzer cobas e 411 (Roche) at the Arab American University of Palestine Laboratory. The assay is an immunoassay that uses a recombinant protein representing the nucleocapsid (N) antigen. Serum samples were tested using Elecsys Anti-SARS-CoV-2 Serum samples in which the nucleocapsid (N) antigen was not detected were run using Elecsys Anti-SARS-CoV-2 S by using the Cobas Analyzer cobas e 411 (Roch). The assay detects antibodies to SARS-CoV-2 spike protein RBD which are produced by mRNA vaccines. Samples from vaccinated and recovered persons with detected SARS-CoV-2 anti N

and SARS-CoV-2 anti S antibodies were run as positive controls. Blood samples were centrifuged, labelled, stored and refrigerated at AAUP laboratory.

Statistical Analysis

Both univariate and bivariate inferential statistical methods were used for statistical analysis. Confidence interval using 95% confidence levels are used for estimation the seroprevalence across different segments within the Palestinian adult population living in the West Bank region. The lower and upper confidence limits of were calculated. Cross-tabulation method was used to explore bivariate relationships between seroprevalence and gender among other background variables. Chi-square test was utilized for doing testing if the bivariate relations are statistically significant.

RESULTS

Sample Characteristics

In total, 1451 participants were enrolled in the study in which 911 undertook serological testing and blood sampling. Among these, 50.8% were males, 64.4% were married, 27.3% finished preparatory school, and 74.4% were non-refugees. The mean age of participants is 37.6.

		N	%
Gender	Male	737	50.8%
	Female	714	49.2%
Marital Status	Never married	377	26.0%
	Engaged	33	2.3%
	Married	935	64.4%
	Divorced	21	1.4%
	Widowed	81	5.6%
	Separated	5	0.3%
Highest Degree Obtained	illiterate	57	3.9%
	Knows how to read and write	68	4.7%
	Elementary	216	14.9%
	Preparatory	396	27.3%
	Secondary	336	23.2%
	Two or one year diploma	81	5.6%
	Bachelor	273	18.8%
	Higher diploma	2	0.2%
	Masters	18	1.3%

	Ph.D.	3	0.2%
Refugee Status	Registered refugee	357	24.6%
	Unregistered refugee	15	1.0%
	Not a refugee	1078	74.3%
Age category in years	18-29	561	38.6%
	30 -49	568	39.2%
	50 +	322	22.2%

		Count	Column Valid N %
Blood Type	" A+"	346	23.8%
	"A-"	30	2.0%
	" B+"	87	6.0%
	"B-"	14	1.0%
	" O+"	335	23.1%
	"O-"	61	4.2%
	" AB+"	53	3.7%
	" AB-"	11	0.7%
	"Don't Know"	514	35.5%
	Total	1451	100.0%
Do you suffer from diabetes ?	Yes	114	7.8%
	No	1337	92.2%
	Total	1451	100.0%
Do you suffer from cancer?	Yes	10	0.7%
	No	1441	99.3%
	Total	1451	100.0%
Do you suffer from heart disease?	Yes	57	3.9%
	No	1394	96.1%
	Total	1451	100.0%
Do you suffer from high blood pressure?	Yes	150	10.3%
	No	1301	89.7%
	Total	1451	100.0%
Do you suffer from asthma?	Yes	30	2.0%
	No	1421	98.0%

	Total	1451	100.0%
Do you suffer from kidney disease?	Yes	8	0.5%
	No	1443	99.5%
	Total	1451	100.0%
Do you suffer from diseases related to the nervous system?	Yes	27	1.8%
	No	1424	98.2%
	Total	1451	100.0%

The main findings of the survey showed that a large majority of adult Palestinians (75.9%) developed antibodies against COVID-19. The results did not show significant difference (P-value=0.23) between males (74.2%) and females (77.5%) (Table 3).

			Gender		Total
			Male	Female	
Antibodies test result	Negative	Count	114	105	219
		% within Gender	25.8%	22.4%	24.1%
	Positive	Count	328	363	691
		% within Gender	74.2%	77.6%	75.9%
Total	Count	442	468	910	
	% within Gender	100.0%	100.0%	100.0%	

Chi-Square Tests

	Value	Df	Asymptotic Significance (2-sided)	Exact Sig. (2-sided)	Exact Sig. (1-sided)
Pearson Chi-Square	1.401 ^a	1	.237		
Continuity Correction ^b	1.223	1	.269		
Likelihood Ratio	1.401	1	.237		
Fisher's Exact Test				.245	.134
Linear-by-Linear Association	1.399	1	.237		
N of Valid Cases	910				

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 106.37.

b. Computed only for a 2x2 table

Unlike gender, as seen in Figure 1, the study results showed quite a significant difference (P-value=0.000) in antibodies prevalence across age groups in the Palestinians society (Figure 1: Percentage of individuals aged 18 years or older who developed antibodies against SARS-CoV-2 according to gender, 2022). As can be seen in Figure 2, the youngest age group (18-29 years) recorded the lowest prevalence of antibodies (69.2%), while the age group (30 -50 years) showed a prevalence of 77.9%. While the older group (50 years or older) got the highest prevalence of antibodies (84.1%) (Figure 2: Percentage of individuals aged 18 years or older who developed antibodies against SARS-CoV-2 according to age, 2022). Such result could be attributed to the fact that the older population categories got more vaccinated than the younger population categories (Table 4: Antibodies test result by age category).

		Age category in years			Total	
		18-29	30 -49	50 +		
Antibodies test result	Negative	Count	113	71	35	219
		% within Age category in years	30.8%	22.0%	15.8%	24.1%
	Positive	Count	254	251	186	691
		% within Age category in years	69.2%	78.0%	84.2%	75.9%
Total		Count	367	322	221	910
		% within Age category in years	100.0%	100.0%	100.0%	100.0%

Chi-Square Tests

	Value	df	Asymptotic Significance (2-sided)
Pearson Chi-Square	17.986 ^a	2	.000
Likelihood Ratio	18.297	2	.000
Linear-by-Linear Association	17.789	1	.000
N of Valid Cases	910		

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 53.19.

An important factor that explained the variation in levels of antibodies prevalence is the vaccination and infection status among the Palestinian population. A new variable was

computed based on the infection status with Covid-19 and the vaccination status. The new variable was used to segment the Palestinian population over the age of 18 into four categories described as follows: a) individuals who got infected and got vaccinated, b) individuals who got infected and did not get vaccinated, c) individuals who did not get infected and got vaccinated, d) individuals who did not get infected and did not get vaccinated.

As can be seen in Figure 3, the largest group of individuals within the Palestinian adult population living in the West Bank region are those who did not get infected and got vaccinated (46.4%) followed by the second largest group, which represents those who did not get vaccinated and reported (thought) that they did not get infected (40.0%) (Figure 3: Distribution of vaccination and Covid-19 infection status for adult Palestinians living in the West Bank region of Palestine, 2022).

Our findings showed a strong bivariate relationship between antibody test results and infection-vaccination status (P-value=0.000) (Table 5). It is evident, the antibodies prevalence among those who did not get infected and got vaccinated is 94.0% in comparison to 45.2% among those who reported that they did not get vaccinated and did not get infected as well. Interestingly, 45.0% of those who did not get vaccinated and reported that they did not get infected with Covid-19 actually got infected without knowing, concluding this group of the population were asymptomatic to the infection.

Table (5): Vaccination and Covid-19 infection status as reported by the respondents Antibodies test result.					
			Antibodies test result		Total
			Negative	Positive	
Vaccination and Covid-19 infection status as reported by the respondents	Got infected with Covid-19 and got vaccinated	Count	1 1.7%	59 98.3%	60 100.0%
	Got infected with Covid-19 and did not get vaccinated	Count	4 5.6%	67 94.4%	71 100.0%
	Did not get infected with Covid-19 and got vaccinated	Count	26 6.0%	410 94.0%	436 100.0%
	Did not get infected with Covid-19 and did not get vaccinated.	Count	188 54.8%	155 45.2%	343 100.0%
Total		Count	219 24.1%	691 75.9%	910 100.0%

Chi-Square Tests

	Value	Df	Asymptotic Significance (2-sided)
Pearson Chi-Square	285.275 ^a	3	.000
Likelihood Ratio	294.040	3	.000
Linear-by-Linear Association	62.356	1	.000
N of Valid Cases	910		

a. 0 cells (0.0%) have expected count less than 5. The minimum expected count is 14.44.

DISCUSSION

The present large-scale study reports on the seroprevalence of anti-SARS-CoV-2 IgG antibodies between September 2021 and October 2021. To the best of our knowledge, this is the first seroepidemiological study describing the seroprevalence and the dynamics of antibodies after positive PCR-test or vaccination. There have not been many studies assessing seroprevalence after the beginning of vaccinations. Seroprevalence of COVID-19 one and half years after the start of the pandemic and several months after the vaccination rollout was 75.9%, varying among age groups, with the youngest age group having the highest seroprevalence. The high IgG+ rate observed in our cohort was surely influenced by the inclusion criteria. However, this is the strength of the data provided herein. This finding was similar to a study conducted in Chile in which IgG positivity reached 77.4% for recipients of the CoronaVac vaccine five months after initiation of the vaccination [14]. There was no difference in gender for IgG positivity, which is inconsistent with other studies which found a statistical significance between IgG positivity and gender.

Two years after the start of the COVID-19 pandemic the actual prevalence of infection is still underestimated compared with PCR-confirmed COVID-19 cases. Older compared with younger individuals have lower antibody levels after vaccination. Approximately, 40% of the Palestinian adult population over the age of 18 years thought they were not infected and did not make the effort to get vaccinated. The study's findings showed 45% of those who thought they were not infected and did not get vaccinated, tested positive for SARS Covid-2 antibodies. By multiplying these two percentages, one can conclude that 18% of the Palestinian adult population who are over the age 18 got infected with SARS Covid-2 without knowing. This group of people could have contributed to a faster transmission rate in the spread of the virus, since they were asymptomatic. Governments and public health officials should put more effort to detect asymptomatic cases through conducting seroprevalence surveys on a regular basis and develop regulations to encourage more people to get vaccinated.

Acknowledgements

The authors would like to thank PCBS staff who participated and managed data collection process. We would like to thank AAUP nursing school for the work they did on blood sample collection from participants. Finally, we would like to thank AAUP lab technicians and manager for their hard working on the blood samples analysis.

Contributors

Original Draft—Faisal Awartani. Writing Editing and Reviewing—Faisal Awartani, Nour Qutub, Mohammed Asia, Waleed Theib. Lab Tests—Nour Qutub. Data Analysis and Visualization--Faisal Awartani.

Funding

The authors have not declared any specific grant from any funding agency in the public, commercial or non-for-profit sector.

Competing Interests

None Declared.

Patient consent for publication

Not required.

REFERENCE

- 1 World Health Organization. WHO coronavirus (COVID-19) dashboard. Geneva: World Health Organization; 2021. <https://covid19.who.int/table> (accessed 12 Mar 2022).
- 2 Cheng MP, Papenburg J, Desjardins M, et al. Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review. *Ann Intern Med.* 2020;172(11):726-34.
- 3 Lieberman-Cribbin W, Tuminello S, Flores RM, et al. Disparities in COVID-19 Testing and Positivity in New York City. *Am J Prev Med.* 2020;59(3):326-32.
- 4 Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living systematic review and meta-analysis. *PLoS Med.* 2020;17(9):e1003346.
- 5 Busch MP, Stone M. Serosurveillance for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Incidence Using Global Blood Donor Populations. *Clin Infect Dis.* 2021;72(2):254-6.
- 6 Havers FP, Reed C, Lim T, et al. Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020. *JAMA Intern Med.* 2020.
- 7 Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US as of September 2020. *JAMA Intern Med.* 2021;181(4):450-60.

8 Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. *J Infect.* 2020;80(6):e1-e13.

9 McLaughlin CC, Doll MK, Morrison KT, et al. High Community SARS-CoV-2 Antibody Seroprevalence in a Ski Resort Community, Blaine County, Idaho, US. Preliminary Results. *medRxiv.* 2020:2020.07.19.20157198.

10 Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al. Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis. *PLoS One.* 2021;16(6):e0252617.

11 Worldometer. State of Palestine: Coronavirus cases. 2022. <https://www.worldometers.info/coronavirus/country/state-of-palestine> (accessed 17 Mar 2022).

12 Qutob N, Awartani F, Salah Z, et al. Seroprevalence of SARS-CoV-2 in Palestine: a cross-sectional seroepidemiological study. *medRxiv.* 2020:2020.08.28.20180083.

13 Maraqa B, Basha W, Khayyat R, et al. Prevalence of SARS-CoV-2 antibodies in the Palestinian population: A primary health center-based cross-sectional study. *PLoS One.* 2021;16(10):e0258255.

14 Sauré D, O'Ryan M, Torres JP, et al. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study. *The Lancet Infectious Diseases.* 2022;22(1):56-63.

Figure (1): Percentage of individuals aged 18 years or older who developed antibodies against SARS-CoV-2 according to gender.




Figure (2): Percentage of individuals aged 18 years or older who developed antibodies against SARS-CoV-2 according to age.




Figure (3): Distribution of vaccination and Covid-19 infection status for adult Palestinians living in the West Bank region of Palestine.

